This Article  • References  • Full text PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on HighWire  • Citing articles on Web of Science (7)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

NARENDRA KRISHNA, B.Sc., M.B.B.S.; MAYER J. MANN, B.A.; IRVING H. LEOPOLD, M.D., D.Sc. (Med.)

Arch Ophthalmol. 1961;65(3):338-344.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

"Monoamine oxidase may now be defined as the enzyme which is responsible for the oxidative deamination of such monoamines as adrenaline, butylamine, and tyramine. The enzyme is inhibited by iproniazid (1x10^-4 M) but not by cyanide or isoniazid (1x10⁴ M). More recently it has been shown that 5-hydroxytryptamine (serotonin) and 3-4-dihydroxyphenylethylamine (dopamine) are amongst the most rapidly metabolized of the physiologically active substrates of the enzyme." This statement of Davison,¹ coupled with the recent availability of specific and irreversible monoamine oxidase inhibitors in increasing numbers,² attests to the renewed interest in the physiological role of the enzyme and the pharmacological significance of the inhibitors.

These advances in our knowledge of the nature of the enzyme and its inhibitors stimulated the present investigation of their role in the ocular tissues from a functional and therapeutic point of view. It has been shown elsewhere that not only large . . . [Full Text PDF of this Article]

Author Affiliations
Philadelphia

From the Departments of Physiology and Ophthalmology, Graduate School of Medicine of the University of Pennsylvania and the Research Department of the Wills Eye Hospital.

Footnotes
Submitted for publication Aug. 10, 1960.

Part of this investigation was carried out during Dr. Krishna's tenure of the "Fight for Sight" research fellowship (1957-1959) of the National Council to Combat Blindness; Inc., New York.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?